軽度の認知障害におけるホリネステラゼ阻害剤のホリネジック白質の整体性に対する長期的影響:拡散MRI研究
1School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Journal of Alzheimer's disease reports
|September 2, 2025
まとめ
コリンエステラゼ阻害剤 (ChEIs) は,特に特定の領域における早期の軽度の認知障害 (MCI) の白質減少を遅らせます. 認知機能が著しく低下する前に 治療が始まれば 効果が最大になります
科学分野:
- 神経イメージング
- 神経変性
- 薬理学について
背景:
- Meynertの塩素原核の退化は,アルツハイマー病 (AD) の認知機能低下に寄与する.
- 慢性疾患では,胆固醇管の微小構造的損傷が体積縮小に先行することが多い.
- ホワイトマターの完全性に対するコレネステラス阻害剤 (ChEIs) の作用は十分に理解されていません.
研究 の 目的:
- 軽度の認知障害 (MCI) を有する個体において,ChEIsが主要なコレリン伝達経路の微細構造的衰退を遅らせるかどうかを調査する.
- 基礎認知状態が,CHEIが白質の整体性に影響するかどうかを判断する.
主な方法:
- MCIの被験者における白質の整合性 (微分アニソトロピーと平均拡散性) を分析するために,拡散テンサ画像 (DTI) を2年間使用した.
- この研究では,CHEI (ドネペジルまたはリバスティグミン) で治療された46人のMCI被験者と,未治療のMCI被験者62人を対象とした.
- 統計モデルでは,薬剤,時間,および基礎認知状態 (ADAS- Cog13) の間の相互作用を,共変数で調整した.
主要な成果:
- すべてのグループでシングラムバンドル (CGC) の進行性退化が観察されました.
- 微小構造的衰退 (FA損失の減少とMDの増加) が特定の経路 (CGC,EC,PTR) で遅いことが示された.
- 薬剤の作用は,未切除のファシキュルス (UNC) に見られませんでした.
結論:
- ChEIは,MCIの白質を,特に初期段階において,経路特異的な,段階依存の保護を提供します.
- 認知機能が著しく低下する前に ChEI 治療を開始することは,白質の整合性を保つのに不可欠です.
- ステージに合わせた介入は,白質の健康を維持するためにプロドラムアルツハイマー病に必要なものです.
さらに関連する動画
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
9.9K
08:36Development of an Uncomplicated Mild Traumatic Brain Injury Model Modified by Weight-Drop Method and Evidenced by Magnetic Resonance Imaging
Published on: April 11, 2025
484
関連する概念動画
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
825
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
825
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.1K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666